Last reviewed · How we verify
grass pollen extract
At a glance
| Generic name | grass pollen extract |
|---|---|
| Also known as | Placebo control |
| Sponsor | Artu Biologicals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Resolution of Allergic Inflammation (NA)
- Determination of Blomia Tropicalis Allergen Extract in Prick Test Units (NA)
- Documentation of Efficacy of Intralymphatic Allergen Immunotherapy (PHASE3)
- Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction (PHASE2)
- Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study (EARLY_PHASE1)
- Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract (PHASE1, PHASE2)
- Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen (PHASE3)
- Quercus Ilex and Quercus Robur Allergen Extracts Standardisation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- grass pollen extract CI brief — competitive landscape report
- grass pollen extract updates RSS · CI watch RSS
- Artu Biologicals portfolio CI